Vigamox instructions for use
Please note that before buying the drug Vigamox, you should carefully read the instructions for use, methods of application and dosage, as well as other useful information on the drug Vigamox. On the site "Encyclopaedia of Diseases" you will find all the necessary information: instructions for proper use, recommended dosage, contraindications, as well as reviews of patients who have already used this medication.
Vigamox - Indications for use
Local treatment of conjunctivitis caused by moxifloxacin-sensitive microorganisms.
Form release: eye drops, bottle 3 and 5 ml.
Vigamox - Composition
In 1 ml of eye drops contains:
The main active substance: moxifloxacin hydrochloride 5.45 mg (corresponding to 5 mg moxifloxacin);
Auxiliary components: boric acid, sodium chloride, sodium hydroxide and / or hydrochloric acid, purified water.
Vigamox is an antimicrobial agent with a bactericidal effect from the group of fluoroquinolones.
Vigamox affects a wide range of microorganisms - gram-negative and gram-positive bacteria, anaerobes, atypical and acid-fast bacteria: Chlamydia spp., Legionella spp., Mycoplasma spp. It is also effective against strains of microorganisms resistant to macrolides and resistant to beta-lactam antibiotics.
Vigamox affects the following groups of pathogens: Gram-positive - Staphylococcus aureus (including methicillin-resistant colonies), Streptococcus pyogenes (group A), Streptococcus pneumoniae (including colonies resistant to macrolides and penicillin); Gram-negative - Haemophilus influenzae, Moraxella catarrhalis, Haemophilus parainfluenzae, Enterobacter cloacae, Klebsiella pneumoniae, Escherichia coli; atypical - Mycoplasma pneumoniae, Chlamydia pneumoniae.
The following microorganisms are susceptible to moxifloxacin in in vitro studies, but safety and efficacy in the treatment of these infections has not been proven. To such pathogens include gram-positive microorganisms: Streptococcus milleri, Str. agalactiae, Streptococcus mitior, Streptococcus dysgalactiae, Staphylococcus epidermidis (including methicillin-sensitive colonies), Staphylococcus saprophyticus, St. cohnii, Staphylococcus hominis, St. haemolyticus, Enterobacter aerogenes, Enterobacter agglomerans, Enterobacter sakazaki, Proteus mirabilis, Enterobacter Intermedius, Proteus vulgaris, Morganella morganii, Providencia stuartii, Providencia rettgeri. Gram-negative microorganisms: Klebsiella oxytoca, Enterobacter aerogenes, Bordetella pertussis, Enterobacter agglomerans, Enterobacter Intermedius, Proteus mirabilis, Proteus vulgaris, Enterobacter sakazaki, Providencia rettgeri, Morganella morgana, Providencia stuartii. Anaerobic microorganisms: Bacteroides distasonis, Bacteroides fragilis, Bacteroides ovatus, Bacteroides eggerthii, Bacteroides thetaiotaornicron, Bacteroides uniformis, Porphyromonas spp., Porphyromonas anaerobius, Fusobacterium spp., Porphyromonas asaccharolyticus, Porphyromonas magnus, Propionibacterium spp., Clostridium perfringens, Cl. ramosum, Prevotella spp. Atypical microorganisms: Caxiella burnettii, Legionella pneumophila.
The effect of moxifloxacin depends on its content in tissues and blood. The minimum bactericidal concentrations are almost equal to the minimum inhibitory concentrations.
Mechanisms of resistance development, which inactivating cephalosporins, penicillins, macrolides, tetracyclines, aminoglycosides do not affect the antibacterial effect of moxifloxacin. Cross-resistance between these groups of drugs and moxifloxacin is absent. Plasmid-mediated pathway of development of resistance was also not noted. The incidence of resistance to moxifloxacin is low. In vitro studies have shown that, due to a number of consecutive mutations, resistance to the drug develops slowly. Multiple exposure to microorganisms of moxifloxacin in submminimal inhibitory concentrations improves the MIC performance slightly. Between the preparations of the fluoroquinolone series, cross resistance is noted, however, some anaerobic and gram-positive microorganisms that are resistant to other fluoroquinolones remain sensitive to moxifloxacin.
Vigamox - Application
Drops of Vigamox are instilled in the diseased eye (or eyes) for 4 days 1 drop 3 times a day. After removing the cap, do not touch the foreign objects with the tip of the pipette. this can lead to microbial contamination of the solution.
The use of Vagamox drops in children and newborns is also highly effective and safe, so their use is possible at the same dose as in adults.
Vigamox - Side effects
Local side effects include: dry eyes, itching, transient discomfort, blurred vision, subconjunctival bleeding, keratitis.
In rare cases, the systemic effect can manifest itself: respiratory failure, pharyngitis, angioedema Quincke , headache, loss of consciousness.
Vigamox - Contraindications
Eye drops Vigamox do not apply with increased sensitivity to the main or auxiliary components of the drug.
Vigamox during pregnancy
Vigamox is prescribed according to strict indications, if there is no effect of treatment with drugs of other groups.
Interaction with other drugs
Local application excludes the possibility of interaction moxifloxacin with other drugs.
Vigamox - Overdose
Overdose is impossible because of the limited space of the conjunctival sac. Accidental oral administration of the drug also does not cause intoxication.
With prolonged use of Vigamox, like any other antibacterial agent, excessive reproduction of microorganisms resistant to the drug can occur. In case of development of superinfection it is recommended to consider alternative methods of treatment.
If any side effects occur, you must stop using Vigamox.
In a closed bottle at a temperature of 20-25 degrees Celsius.
We want to pay special attention to the fact that the description of the drug Vigamox is presented for informational purposes only! For more accurate and detailed information about the drug Vigamox, please refer exclusively to the manufacturer's annotation! Do not self-medicate! You should definitely consult a doctor before starting the drug!